Logo
x

Search

Subscribe Now

Blueprint Medicines

Blueprint Medicines’s Ayvakyt Receives EC’s Approval for the Treatment of Adult Patients with Indolent Systemic Mastocytosis (ISM)

Blueprint Medicines’s Ayvakyt Receives EC’s Approval for the Treatment of Adult Patients with Indolent Systemic Mastocytosis (ISM)

  • December 13, 2023
Blueprint Medicines Published (PIONEER) Trial Results of Ayvakit (avapritinib) for the Treatment of Indolent Systemic Mastocytosis in the NEJM

Blueprint Medicines Published (PIONEER) Trial Results of Ayvakit (avapritinib) for the Treatment of Indolent Systemic Mastocytosis...

  • May 24, 2023
Blueprint Medicines Presents P-II Trial (PIONEER) of Ayvakit (avapritinib) for Indolent Systemic Mastocytosis at AAAAI 2023

Blueprint Medicines Presents P-II Trial (PIONEER) of Ayvakit (avapritinib) for Indolent Systemic Mastocytosis at AAAAI 2023

  • February 27, 2023
Nicolas Paquette-Lamontagne, VP, Medical Affairs at Blueprint Medicines Shares his Views on Clinical Data of Ayvakit for Patients with Systemic Mastocytosis

Nicolas Paquette-Lamontagne, VP, Medical Affairs at Blueprint Medicines Shares his Views on Clinical Data of Ayvakit for Patients...

  • February 13, 2023
Blueprint Medicines Receives the US FDA’s Acceptance of sNDA for Ayvakit (avapritinib) to Treat Indolent Systemic Mastocytosis

Blueprint Medicines Receives the US FDA’s Acceptance of sNDA for Ayvakit (avapritinib) to Treat Indolent Systemic Mastocytosis

  • January 24, 2023
Blueprint Medicines Reports (PIONEER) Trial Results of Ayvakit (avapritinib) for the Treatment of Non-Advanced Systemic Mastocytosis

Blueprint Medicines Reports (PIONEER) Trial Results of Ayvakit (avapritinib) for the Treatment of Non-Advanced Systemic Mastocytos...

  • August 18, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.